The SNC-80 series of nonpeptidic agonists for the delta-opioid receptor are being developed as po... more The SNC-80 series of nonpeptidic agonists for the delta-opioid receptor are being developed as potential analgesic drugs. It is important to understand their acute and chronic effects at human delta-opioid receptors. Thus, we measured the ability of SNC-80 and [D-Pen2,4'-Cl-Phe4,D-Pen5]enkephalin to inhibit forskolin-stimulated adenylyl cyclase activity in recombinant Chinese hamster ovary cells stably expressing the cloned human delta-opioid receptor. The calculated EC50 values for [D-Pen2,4'-Cl-Phe4,D-Pen5]enkephalin and SNC-80 were 0.6 +/- 0.1 nM and 6.3 +/- 0.1 nM, respectively. Pretreatment of these cells with SNC-80 (100 nM) for 24 hr produced 1) a time-dependent reduction of delta receptor density, as measured by radioligand binding studies with [3H]naltrindole; 2) a shift in the EC50 value of SNC-80 from 7.7 +/- 4.2 nM to 44.1 +/- 12 nM, as measured by the cyclic AMP assay; 3) a reduction in the maximum inhibition of adenylyl cyclase activity from 86% to 48%; 4) a marked increase in the forskolin stimulation of basal cyclic AMP accumulation by nearly 100% (from 442 pmol/mg of protein to 824 pmol/mg of protein); and 5) a 5-fold increase in forskolin-stimulated cyclic AMP accumulation after addition of naltrindole. These studies showed that SNC-80 produced desensitization and down-regulation of human delta-opioid receptors in recombinant Chinese hamster ovary cells after chronic treatment and that this effect was associated with an increase in adenylyl cyclase activity.
Journal of Pharmacology and Experimental Therapeutics, Jun 2, 2009
Studies have shown that long-term (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (mo... more Studies have shown that long-term (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (morphine) treatment increases the sensitivity to painful heat stimuli (thermal hyperalgesia). The cellular adaptations contributing to sustained morphine-mediated pain sensitization are not fully understood. It was shown previously (J Neurosci 22:6747–6755, 2002) that sustained morphine exposure augments pain neurotransmitter [such as calcitonin gene-related peptide (CGRP)] release in the dorsal horn of the spinal cord in response to the heat-sensing transient receptor potential vanilloid 1 receptor agonist 8-methyl-N-vanillyl-6-nonenamide (capsaicin). In the present study, we demonstrate that sustained morphine-mediated augmentation of CGRP release from isolated primary sensory dorsal root ganglion neurons is dependent on protein kinase A and Raf-1 kinase. Our data indicate that, in addition to neural system adaptations, sustained opioid agonist treatment also produces intracellular compensatory adaptations in primary sensory neurons, leading to augmentation of evoked pain neurotransmitter release from these cells.
We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Por... more We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein gamma2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the gamma2 subunit (Ggamma2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a delta-opioid receptor agonist. In the present study, we examined the involvement of Ggamma2 in antinociception mediated by other (mu- or kappa-opioid, cannabinoid, alpha2-adrenoreceptor) analgesic agents in a warm (55 degrees C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein gamma2 subunits in supraspinal antinociception.
The specific binding of [3H] antagonists to muscarinic receptors from neuronal tissue has been de... more The specific binding of [3H] antagonists to muscarinic receptors from neuronal tissue has been demonstrated by several investigators (6,19,24,28,32,37). In each case, the binding of [3H] antagonists is consistent with the law of mass action for a single class of independent receptors. Similarly, the results of antagonist/ [3H] antagonist competition experiments are also consistent with the law of mass action (23). Perhaps the most convincing evidence demonstrating that the binding of [3H] antagonists represents a specific interaction with the muscarinic receptor is the excellent quantitative agreement between the values of dissociation constants determined by binding experiments and by antagonism of agonist induced contractions of the guinea pig ileum (8,10).
There exists a saturable, high-affinity, stereospecific, regionally and pharmacologically specifi... more There exists a saturable, high-affinity, stereospecific, regionally and pharmacologically specific, neuronally localized benzodiazepine receptor in mammalian brain, which has a development profile similar to other neurotransmitter receptors. This receptor appears to be modulated by gamma-aminobutyric acid and selected divalent cations, and chloride ions increase the affinity of the receptor for benzodiazepines. Several benzodiazepines were shown to bind irreversibly to the receptor upon exposure to ultraviolet light and these agents can be used to facilitate solubilization and purification of the benzodiazepine receptor. Although several substances have been suggested to be the endogenous ligand, none has achieved the acceptance given to other neurotransmitters or neuromodulators, e.g., enkephalins and endorphins.
The SNC-80 series of nonpeptidic agonists for the delta-opioid receptor are being developed as po... more The SNC-80 series of nonpeptidic agonists for the delta-opioid receptor are being developed as potential analgesic drugs. It is important to understand their acute and chronic effects at human delta-opioid receptors. Thus, we measured the ability of SNC-80 and [D-Pen2,4'-Cl-Phe4,D-Pen5]enkephalin to inhibit forskolin-stimulated adenylyl cyclase activity in recombinant Chinese hamster ovary cells stably expressing the cloned human delta-opioid receptor. The calculated EC50 values for [D-Pen2,4'-Cl-Phe4,D-Pen5]enkephalin and SNC-80 were 0.6 +/- 0.1 nM and 6.3 +/- 0.1 nM, respectively. Pretreatment of these cells with SNC-80 (100 nM) for 24 hr produced 1) a time-dependent reduction of delta receptor density, as measured by radioligand binding studies with [3H]naltrindole; 2) a shift in the EC50 value of SNC-80 from 7.7 +/- 4.2 nM to 44.1 +/- 12 nM, as measured by the cyclic AMP assay; 3) a reduction in the maximum inhibition of adenylyl cyclase activity from 86% to 48%; 4) a marked increase in the forskolin stimulation of basal cyclic AMP accumulation by nearly 100% (from 442 pmol/mg of protein to 824 pmol/mg of protein); and 5) a 5-fold increase in forskolin-stimulated cyclic AMP accumulation after addition of naltrindole. These studies showed that SNC-80 produced desensitization and down-regulation of human delta-opioid receptors in recombinant Chinese hamster ovary cells after chronic treatment and that this effect was associated with an increase in adenylyl cyclase activity.
Journal of Pharmacology and Experimental Therapeutics, Jun 2, 2009
Studies have shown that long-term (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (mo... more Studies have shown that long-term (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (morphine) treatment increases the sensitivity to painful heat stimuli (thermal hyperalgesia). The cellular adaptations contributing to sustained morphine-mediated pain sensitization are not fully understood. It was shown previously (J Neurosci 22:6747–6755, 2002) that sustained morphine exposure augments pain neurotransmitter [such as calcitonin gene-related peptide (CGRP)] release in the dorsal horn of the spinal cord in response to the heat-sensing transient receptor potential vanilloid 1 receptor agonist 8-methyl-N-vanillyl-6-nonenamide (capsaicin). In the present study, we demonstrate that sustained morphine-mediated augmentation of CGRP release from isolated primary sensory dorsal root ganglion neurons is dependent on protein kinase A and Raf-1 kinase. Our data indicate that, in addition to neural system adaptations, sustained opioid agonist treatment also produces intracellular compensatory adaptations in primary sensory neurons, leading to augmentation of evoked pain neurotransmitter release from these cells.
We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Por... more We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein gamma2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the gamma2 subunit (Ggamma2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a delta-opioid receptor agonist. In the present study, we examined the involvement of Ggamma2 in antinociception mediated by other (mu- or kappa-opioid, cannabinoid, alpha2-adrenoreceptor) analgesic agents in a warm (55 degrees C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein gamma2 subunits in supraspinal antinociception.
The specific binding of [3H] antagonists to muscarinic receptors from neuronal tissue has been de... more The specific binding of [3H] antagonists to muscarinic receptors from neuronal tissue has been demonstrated by several investigators (6,19,24,28,32,37). In each case, the binding of [3H] antagonists is consistent with the law of mass action for a single class of independent receptors. Similarly, the results of antagonist/ [3H] antagonist competition experiments are also consistent with the law of mass action (23). Perhaps the most convincing evidence demonstrating that the binding of [3H] antagonists represents a specific interaction with the muscarinic receptor is the excellent quantitative agreement between the values of dissociation constants determined by binding experiments and by antagonism of agonist induced contractions of the guinea pig ileum (8,10).
There exists a saturable, high-affinity, stereospecific, regionally and pharmacologically specifi... more There exists a saturable, high-affinity, stereospecific, regionally and pharmacologically specific, neuronally localized benzodiazepine receptor in mammalian brain, which has a development profile similar to other neurotransmitter receptors. This receptor appears to be modulated by gamma-aminobutyric acid and selected divalent cations, and chloride ions increase the affinity of the receptor for benzodiazepines. Several benzodiazepines were shown to bind irreversibly to the receptor upon exposure to ultraviolet light and these agents can be used to facilitate solubilization and purification of the benzodiazepine receptor. Although several substances have been suggested to be the endogenous ligand, none has achieved the acceptance given to other neurotransmitters or neuromodulators, e.g., enkephalins and endorphins.
Uploads
Papers by William Roeske